Who is sponsoring NCT02161744?

NCT02161744 is sponsored by Arkansas Heart Hospital.

What drugs are being tested in NCT02161744?

Interventions in NCT02161744: ADSCs administration.

What condition does NCT02161744 study?

NCT02161744 studies Chronic Obstructive Pulmonary Disease.

Is NCT02161744 still recruiting?

NCT02161744 is currently terminated. Last updated 27 January 2020.

Last reviewed 2020-01-27 · How we verify

NCT02161744

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD

Terminated Phase 1 Last updated 27 January 2020

What this trial tests

Phase 1 trial testing ADSCs administration in Chronic Obstructive Pulmonary Disease in 9 participants. Terminated before completion.

Timeline

10 October 2013

Primary endpoint
29 October 2018

29 October 2018

Quick facts

Lead sponsor	Arkansas Heart Hospital
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	10 October 2013
Primary completion	29 October 2018
Estimated completion	29 October 2018
Sites	2 locations across United States

Drugs / interventions tested

ADSCs administration — full drug profile →

Conditions studied

Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →

Sponsor

Arkansas Heart Hospital

Who can join

18 and older, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is: 1.- to assess the safety and tolerability of autologous adipose derived stem cells (aADSC) administered intravenously in patients with chronic obstructive pulmonary disease, and 2.- to assess if this therapy results in less decrease of lung function parameters (FEV1, FEV1/FVC and 6 min walking distance) compared with a control baseline of 6 weeks. Patients will be followed up for 12 months after the therapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Fat Therapeutics: The Clinical Capacity of Adipose-Derived Stem Cells and Exosomes for Human Disease and Tissue Regeneration.
Shukla L, Yuan Y, Shayan R, Greening DW, et al · · 2020 · cited 129× · PMID 32194404 · DOI 10.3389/fphar.2020.00158
Concise Review: Fat and Furious: Harnessing the Full Potential of Adipose-Derived Stromal Vascular Fraction.
Dykstra JA, Facile T, Patrick RJ, Francis KR, et al · · 2017 · cited 77× · PMID 28186685 · DOI 10.1002/sctm.16-0337
Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease?
Broekman W, Khedoe PPSJ, Schepers K, Roelofs H, et al · · 2018 · cited 65× · PMID 29653970 · DOI 10.1136/thoraxjnl-2017-210672
Adipose Stem Cell Translational Applications: From Bench-to-Bedside.
Argentati C, Morena F, Bazzucchi M, Armentano I, et al · · 2018 · cited 63× · PMID 30400641 · DOI 10.3390/ijms19113475
Preclinical Studies of Mesenchymal Stem Cell (MSC) Administration in Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis.
Liu X, Fang Q, Kim H. · · 2016 · cited 45× · PMID 27280283 · DOI 10.1371/journal.pone.0157099
Mesenchymal Stem Cell Administration in Patients with Chronic Obstructive Pulmonary Disease: State of the Science.
Cheng SL, Lin CH, Yao CL. · · 2017 · cited 27× · PMID 28303154 · DOI 10.1155/2017/8916570
Stem cell therapy for chronic obstructive pulmonary disease.
Chen YT, Miao K, Zhou L, Xiong WN. · · 2021 · cited 22× · PMID 34250959 · DOI 10.1097/cm9.0000000000001596
Current therapeutic strategies for respiratory diseases using mesenchymal stem cells.
Wang MY, Zhou TY, Zhang ZD, Liu HY, et al · · 2021 · cited 21× · PMID 34766151 · DOI 10.1002/mco2.74

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

NCT06749262 — Inclined Versus Standard Exercise for COPD Patients · NA · recruiting
NCT07406659 — Different Inspiratory Muscle Trainings in Patients With COPD · NA · recruiting
NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
NCT07069829 — Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo · recruiting

Other Arkansas Heart Hospital trials

Trials by the same sponsor.

NCT05708313 — Effects of 9-18 Weeks of Intensive Cardiac Rehabilitation After a Major Cardiovascular Event in Patients With CVD · NA · completed
NCT03455374 — Diamondback in Peripheral Vascular Disease · NA · terminated
NCT02756884 — Safety and Preliminary Efficacy of Adipose Derived Stem Cells and Low Frequency Ultrasound in PAD · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02161744 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arkansas Heart Hospital
Last refreshed: 27 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02161744.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing